Investment

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

admin
admin

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.

Source: MarketWatch

You Might Also Like

Is gridlock in Washington actually good for stocks? Here’s what historical market data says.
A strategist who called the Asian financial crisis sees parallels with the AI boom
The Nasdaq’s rapid rise to a record is sending a message to investors: Don’t wait for a pullback to buy
Traders expecting a back-to-back rate hike from the Fed in October may have gotten ahead of themselves
Here’s where TSMC is reportedly eyeing a second U.S. site for a chip-making hub
Share This Article
Previous Article Lionel Richie Undergoes Atrial Fibrillation Procedure, ‘Will Be Back on Stage Soon’ After Canceling Next Three Shows
Next Article Wigan and Leigh face conduct probe, says RFL
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *